Cencora

(New York Stock Exchange)
Back to all articles
Bullish +58

Baird raises target for Cencora stock from USD 370 to USD 373

Analyst upgrade AI-generated analysis

πŸ“ˆ Cencora reported fiscal third-quarter revenue of USD 84.80 billion, representing a 5.10% increase from the prior-year quarter.

πŸ’° GAAP diluted earnings per share grew to USD 3.94, up from USD 3.52 in the same period last year.

πŸ“Š Robert W. Baird raised its price target for Cencora stock from USD 370.00 to USD 373.00 on October 12, 2026.

πŸ—“οΈ The company plans to release fiscal fourth-quarter results before the NYSE open on November 4, 2026.

🏒 Cencora serves pharmaceutical manufacturers, hospitals, pharmacies, and other healthcare providers through distribution services.

πŸ’΅ As of October 12, 2026, the company had a market capitalization of USD 63.2 billion.

πŸ“‰ The stock traded within a 52-week range of USD 244.82 to USD 377.54 as of mid-October 2026.

Bullish Signals
  • Cencora reported fiscal third-quarter revenue growth of 5.10% year-over-year, reaching USD 84.80 billion.
  • GAAP diluted earnings per share increased by USD 0.42 to reach USD 3.94 in the fiscal third quarter.
  • Analyst firm Robert W. Baird raised its price target for Cencora stock from USD 370.00 to USD 373.00.
  • The company successfully elected Robert E. Sanchez as an independent director, effective October 1, 2026.
Full Analysis
Cencora Inc. reported strong fiscal third-quarter results, with revenue rising 5.10% to USD 84.80 billion for the period ended June 30, 2026. GAAP diluted earnings per share increased significantly to USD 3.94 from USD 3.52 in the prior-year quarter, reflecting solid operating progress across its distribution and patient-access services. Following these results, investment firm Robert W. Baird raised its price target for Cencora stock from USD 370.00 to USD 373.00 on October 12, 2026. The analyst move provides a fresh bullish reference point as investors await the company's upcoming fiscal fourth-quarter results scheduled for release on November 4, 2026. Cencora continues to serve pharmaceutical manufacturers, hospitals, and pharmacies through its extensive distribution network. With a market capitalization of USD 63.2 billion, the healthcare logistics giant trades under the ticker COR on the NYSE, maintaining a 52-week range between USD 244.82 and USD 377.54 as of mid-October 2026.